Aberrant proteoglycan composition of the glomerular basement membrane in a patient with Denys-Drash syndrome

被引:14
|
作者
vandenHeuvel, LPWJ
Westenend, PJ
vandenBorn, J
Assmann, KJM
Knoers, N
Monnens, LAH
机构
[1] UNIV NIJMEGEN,DEPT PATHOL,6500 HB NIJMEGEN,NETHERLANDS
[2] UNIV NIJMEGEN,DEPT NEPHROL,6500 HB NIJMEGEN,NETHERLANDS
[3] UNIV NIJMEGEN,DEPT HUMAN GENET,6500 HB NIJMEGEN,NETHERLANDS
关键词
chondroitin sulphate proteoglycan; Denys-Drash syndrome; glomerular basement membrane; Wilms' tumour gene;
D O I
10.1093/ndt/10.12.2205
中图分类号
R3 [基础医学]; R4 [临床医学];
学科分类号
1001 ; 1002 ; 100602 ;
摘要
Background. To ascertain whether changes in proteoglycans are involved in the pathogenesis of the nephrotic syndrome in Denys-Drash syndrome (DDS), we analysed the glycosaminoglycan (GAG) content and composition of the glomerular basement membrane (GBM) in one child with this disorder and in children of comparable age who had died from unrelated disorders. Methods. The diagnosis of DDS was confirmed by the presence of a previously described mutation in the WT1 gene (a tumour suppressor gene). The GAG content and composition of the GEM and tubular basement membrane (TBM), both in the Denys-Drash patient as well as age-matched control infants, was analysed by biochemical studies and indirect immunofluorescence studies. Finally we investigated the urinary GAG excretion of the Drash patient. Results. The biochemical studies revealed that the total GAG content in the GEM as well as TBM was comparable in the Drash patient and the control group. However, the GAG composition of the GEM of the patient was clearly different, with relatively more chondroitin sulphate. The urinary GAG content (expressed as mg GAG/mmol creatinine) was elevated in the Denys-Drash patient due to an increased heparan sulphate (HS(GAG)) excretion. Indirect immunofluorescence (IF) studies for the core protein of human GEM heparan sulphate proteoglycan (HSPG) showed a similar linear staining of all renal basement membranes in the patient and the controls. A monoclonal antibody directed against the HS chain of HSPG (MoAb 403) displayed a strong GEM and a weak TBM staining of normal kidneys. Kidney tissue from the Drash patient displayed a reduced staining of the GEM with MoAb 403. IF studies for chondroitin sulphate proteoglycan (CSPG) showed increased staining of the mesangium and glomerular capillary loops in the Denys-Drash patient which is in agreement with the biochemical studies. No discernible differences in distribution or quality of staining with antibodies against collagen type IV and laminin were observed. Conclusions. These biochemical and immunohistochemical results indicate that in our patient the proteoglycan composition of the GEM is altered. This alteration may play a role in the pathogenesis of proteinuria in this syndrome.
引用
收藏
页码:2205 / 2211
页数:7
相关论文
共 50 条
  • [41] Denys-Drash syndrome with cerebral atrophy and neurological deficit - a case report
    Doviltyte, Zina
    Dobiliene, Diana
    Masalskiene, Jurate
    Rudaitis, Sarunas
    Naujokaitis, Antanas
    PEDIATRIC NEPHROLOGY, 2024, 39 (01) : S313 - S314
  • [42] A newly identified exonic mutation of the WT1 gene in a patient with Denys-Drash syndrome
    Tsuda, M
    Sakiyama, T
    Owada, M
    Chiba, Y
    ACTA PAEDIATRICA JAPONICA, 1996, 38 (03): : 265 - 266
  • [43] Incomplete Denys-Drash syndrome with multiple congenital anomalies: a case report
    Clowes, Virginia
    Roper, E.
    Paterson, J.
    Firth, H. V.
    JOURNAL OF MEDICAL GENETICS, 2007, 44 : S56 - S56
  • [44] Unusual Presentation of Denys-Drash Syndrome in a Girl with Undisclosed Consumption of Biotin
    Bizzarri, Carla
    Giannone, Germana Antonella
    Gervasoni, Jacopo
    Benedetti, Sabina
    Albanese, Federica
    Dello Strologo, Luca
    Guzzo, Isabella
    Mucciolo, Mafalda
    Camassei, Francesca Diomedi
    Emma, Francesco
    Cappa, Marco
    Porzio, Ottavia
    JOURNAL OF CLINICAL RESEARCH IN PEDIATRIC ENDOCRINOLOGY, 2021, 13 (03) : 347 - 352
  • [45] Long-term outcome in a case series of Denys-Drash syndrome
    Roca, Neus
    Munoz, Marina
    Cruz, Alejandro
    Vilalta, Ramon
    Lara, Enrique
    Ariceta, Gema
    CLINICAL KIDNEY JOURNAL, 2019, 12 (06) : 836 - 839
  • [46] No evidence of WT1 involvement in a Burkitt's lymphoma in a patient with Denys-Drash syndrome
    Perotti, D
    Mondini, P
    Giardini, R
    Ferrari, A
    Massimino, M
    Gambirasio, F
    Pierotti, MA
    Fossati-Bellani, F
    Radice, P
    ANNALS OF ONCOLOGY, 1998, 9 (06) : 627 - 631
  • [47] Regulation of renal EGF receptor expression is normal in Denys-Drash syndrome
    Vicanek, C
    Ferretti, E
    Goodyer, C
    Torban, E
    Moffett, P
    Pelletier, J
    Goodyer, P
    KIDNEY INTERNATIONAL, 1997, 52 (03) : 614 - 619
  • [48] The dysregulated glomerular cell growth in Denys–Drash syndrome
    An Hang Yang
    Jinn Yang Chen
    Be Fun Chen
    Virchows Archiv, 2004, 445 : 305 - 314
  • [49] Refractory hypotension after bilateral nephrectomies in a Denys-Drash patient with phenylketonuria
    Hassinger, Amanda B.
    Garimella, Sudha
    PEDIATRIC NEPHROLOGY, 2013, 28 (02) : 345 - 348
  • [50] A proteomic investigation of glomerular podocytes from a Denys-Drash Syndrome patient with a mutation in the Wilms turn our suppressor gene WT1
    Viney, Rebecca L.
    Morrison, Avril A.
    van den Heuvel, Lambert P.
    Ni, Lan
    Mathieson, Peter W.
    Saleem, Moin A.
    Ladomery, Michael R.
    PROTEOMICS, 2007, 7 (05) : 804 - 815